Literature DB >> 26056800

Insulin-like Growth Factor 2 Gene Expression Molecularly Differentiates Pleuropulmonary Blastoma and Embryonal Rhabdomyosarcoma.

Rajkumar Venkatramani1, Timothy J Triche, Larry Wang, Hiroyuki Shimada, Leo Mascarenhas.   

Abstract

The sarcomatous element in pleuropulmonary blastoma (PPB) is often histologically indistinguishable from embryonal rhabdomyosarcoma (ERMS). A diagnosis of PPB is often made after definitive surgical resection based on pathologic features, most notably the presence of hamartomatous pulmonary elements. Samples from seven PPB patients were obtained from the rhabdomyosarcomatous portion of the tumor by macrodissection. Representative ERMS tumor tissue was selected from 21 ERMS patient samples. Formalin-fixed paraffin-embedded tissue scrolls from each sample were analyzed using the Affymetrix Human Exon arrays. All PPB patients and 7 of 21 ERMS patients were 3 years old and younger. Twenty transcripts (10 annotated, 10 noncoding RNAs) were significantly differentially expressed in ERMS when compared with PPB samples. Insulin-like growth factor 2 (IGF2) was uniformly overexpressed in ERMS (19/21>400) but was expressed at low levels in PPB (P<0.001). Two ERMS cases that had low level IGF2 expression were 3 years and younger of age. No other differences between the 2 approached this degree of significance, despite a common rhabdomyogenic phenotype in the sarcomatous areas of PPB. PPB, unlike most ERMS, appears not to be driven by autocrine IGF2 signaling.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26056800      PMCID: PMC4506202          DOI: 10.1097/MPH.0000000000000382

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  23 in total

1.  Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.

Authors:  D Yee; R E Favoni; G S Lebovic; F Lombana; D R Powell; C P Reynolds; N Rosen
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

2.  Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.

Authors:  O M El-Badry; C Minniti; E C Kohn; P J Houghton; W H Daughaday; L J Helman
Journal:  Cell Growth Differ       Date:  1990-07

3.  Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor.

Authors:  K Raile; A Höflich; U Kessler; Y Yang; M Pfuender; W F Blum; H Kolb; H P Schwarz; W Kiess
Journal:  J Cell Physiol       Date:  1994-06       Impact factor: 6.384

4.  Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth.

Authors:  C C Kappel; M C Velez-Yanguas; S Hirschfeld; L J Helman
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

5.  Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product.

Authors:  H Werner; G G Re; I A Drummond; V P Sukhatme; F J Rauscher; D A Sens; A J Garvin; D LeRoith; C T Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

6.  Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma.

Authors:  S Zhan; D N Shapiro; L J Helman
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

7.  Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome.

Authors:  R Weksberg; D R Shen; Y L Fei; Q L Song; J Squire
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

8.  A new marker for rhabdomyosarcoma. Insulin-like growth factor II.

Authors:  K Yun
Journal:  Lab Invest       Date:  1992-11       Impact factor: 5.662

9.  Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry.

Authors:  Yoav H Messinger; Douglas R Stewart; John R Priest; Gretchen M Williams; Anne K Harris; Kris Ann P Schultz; Jiandong Yang; Leslie Doros; Philip S Rosenberg; D Ashley Hill; Louis P Dehner
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

10.  The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis.

Authors:  Mingzhu Liu; Anna Roth; Min Yu; Robert Morris; Francesca Bersani; Miguel N Rivera; Jun Lu; Toshihiro Shioda; Shobha Vasudevan; Sridhar Ramaswamy; Shyamala Maheswaran; Sven Diederichs; Daniel A Haber
Journal:  Genes Dev       Date:  2013-12-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.